Imugene |
High $0.10 |
Low $0.09 |
Trades 2,797 |
Turnover $4,713,392 |
Volume 50,159,971 |
| 30 June 2023 at 4:59pm | ||||
|
Market Cap (13-Nov) $19,392,378 (199th) |
Close (30-Jun) $0.091 |
Volume (30-Jun) 50,159,971 |
Shortsold (6-Nov) 1,815,355 (0.33%) (364th) |
|
52w High $0.410 |
52w Low $0.030 |
P/E 13.30 |
EPS -0.32 |
Release of Securities from Escrow
IMU released this announcement to the ASX on 10 January 2022, 17:11. The announcement is not marked as price sensitive, and is 1 page(s) in length and 74.52kb in size.
You can view all announcements from IMU and see how they appear on a price chart on the announcements page.
At the date of this announcement, IMU was 3.379% short sold according to ASIC data. It was ranked the 50th most shorted stock on the ASX. It remains ranked 364th as of the latest reported data (06 November 2026).
| Other Recent Announcements from IMU | |
|---|---|
| Change of Director's Interest Notice | 30 June 2023, 16:33 |
| HER-Vaxx induced antibodies correlated with tumour reduction | 30 June 2023, 8:40 |
| Imugene PD1-Vaxx patent extended to 2040 | 29 June 2023, 8:39 |
| Release of Securities from Escrow | 10 January 2022, 17:11 |
| Imugene Receives $6.54 million R&D Tax Incentive | 6 January 2022, 19:37 |
| South Korea HERVaxx Patent Grant | 6 January 2022, 10:22 |
| Imugene completes Phase 1a trial of immunotherapy PD1-Vaxx | 4 January 2022, 9:30 |
If you were already registered, log in here.